Skip to content

Study · Randomized controlled trial · n = 40 · 1990

4 results

A study of octreotide in oesophageal varices.

McKee R

Digestion1 Jan 1990Cited by 46 (Europe PMC)

PMID2185967 (opens in a new tab)DOI10.1159/000200264 (opens in a new tab)PepBankPUB-02185967
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with active variceal bleeding, octreotide and oesophageal tamponade gave comparable bleeding control.

    In plain wordsIn patients with active variceal bleeding, octreotide and oesophageal tamponade controlled bleeding comparably.

    Peptide
    Octreotide
    Outcome
    No significant changeVariceal bleeding control
    Study

    n = 40

    Comparator
    Oesophageal tamponade
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    25 micrograms/h · infusion · 48 hAs given in this study (human).

    Source sentences

    Summary
    The 2 treatments gave comparable control of variceal bleeding.
    1 context sentence
    Summary · context
    In a separate trial, 40 patients with active variceal bleeding were randomized to octreotide infusion (25 micrograms/h for 48 h) or oesophageal tamponade.
  2. 02HumanRandomized controlled trialSafety outcome

    In patients with active variceal bleeding, treatment tolerance was significantly better with octreotide than oesophageal tamponade.

    In plain wordsIn patients with active variceal bleeding, treatment tolerance was better with octreotide than oesophageal tamponade.

    Peptide
    Octreotide
    Outcome
    Direction not reportedTreatment tolerance
    Study

    n = 40

    Comparator
    Oesophageal tamponade
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    25 micrograms/h · infusion · 48 hAs given in this study (human).

    Source sentences

    Summary
    Tolerance of treatment was significantly better in the octreotide group.
    1 context sentence
    Summary · context
    In a separate trial, 40 patients with active variceal bleeding were randomized to octreotide infusion (25 micrograms/h for 48 h) or oesophageal tamponade.
  3. 03HumanNon-randomized trialEfficacy outcome

    In stable cirrhotic patients, the octreotide group had a 30% reduction in transhepatic venous gradient between 0 and 60 min.

    In plain wordsIn stable cirrhotic patients, the transhepatic venous gradient decreased 30% from baseline during octreotide infusion.

    Peptide
    Octreotide
    Outcome
    DecreaseTranshepatic venous gradient
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    25 micrograms/h · infusionAs given in this study (human).

    Measurements

    Transhepatic venous gradient reduction
    30%
    octreotide group, 0 to 60 min

    Source sentences

    Summary
    A comparison of octreotide infusion (25 micrograms/h) and placebo in 16 stable cirrhotic patients revealed a 30% reduction in transhepatic venous gradient between 0 and 60 min in the octreotide group without an effect on systemic haemodynamics.
  4. 04HumanNon-randomized trialEfficacy outcome

    In stable cirrhotic patients, octreotide infusion did not affect systemic haemodynamics.

    In plain wordsIn stable cirrhotic patients, octreotide infusion did not change systemic circulation measures.

    Peptide
    Octreotide
    Outcome
    No significant changeSystemic haemodynamics
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    25 micrograms/h · infusionAs given in this study (human).

    Source sentences

    Summary
    A comparison of octreotide infusion (25 micrograms/h) and placebo in 16 stable cirrhotic patients revealed a 30% reduction in transhepatic venous gradient between 0 and 60 min in the octreotide group without an effect on systemic haemodynamics.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.